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Background: Tendinopathy is a difficult problem to manage and can result in significant patient morbidity. Currently,
the clinical use of platelet-rich plasma (PRP) in painful tendons is widespread but its efficacy remains controversial.
Methods/Design: This study is a single-center, randomized double-blind controlled trial. Eighty patients will be
allocated to have ultrasound (US)-guided needling combined with a leukocyte-depleted (that is, pure) PRP or lidocaine
each alternate week for a total of two interventions. Outcome data will be collected before intervention, and at 6 weeks,
3, 6, and 12 months after intervention. Main outcome measure: Changes in pain and activity levels, as assessed by
Disabilities of the Arm, Shoulder and Hand (DASH-E, Spanish version) score, at 6 months. We will compare the
percentage of patients in each group that achieve a successful treatment defined as a reduction of at least 25% in the
DASH-E score. Secondary outcome measures include changes in DASH-E at 3 and 12 months, changes in pain as
assessed by the visual analogue scale (VAS) at the 6-week, 3-, 6-, and 12-month follow-up, changes in sonographic
features and neovascularity, and percentage of patients in each group with adverse reactions at 3, 6, and 12 months.
Discussion: The results of this study will provide insights into the effect of pure PRP in tendon and may contribute to
identifying the best protocol for PRP application in tendinopathies.
Trial registration: ClinicalTrials.gov: NCT01945528.
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Tendon disorders (tendinopathies) are noteworthy in
sports and occupational settings due to repetitive trauma
and overuse; besides they are prevalent among individ-
uals of all ages, and also part of the ageing process. The
term ‘tendinopathy’ describes painful conditions affect-
ing tendons associated with repetitive strain, overuse,
ageing, degeneration, or poor biomechanics [1]. Tendi-
nopathies worsen quality of life by causing pain and
impairing mobility, decreasing the ability to perform
daily activities, and compromising an active lifestyle.
Current research has produced several biological hy-
pothesis based on histopathological, biochemical, and
clinical findings that show cell apoptosis, angiofibroblastic
features, or abnormal biochemical adaptations, largely* Correspondence: iandia2010@hotmail.com
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stated.suggesting that a failed healing response underlies the
condition [2].
At present, minimally invasive interventions capable of
boosting the healing response or counteracting degen-
erative changes in tendinopathy are being investigated.
Among the emerging technologies, one investigational
biological therapy, platelet-rich plasma (PRP), has been
recently explored in several clinical studies [3]; in par-
ticular, several controlled clinical studies have examined
the effect of PRP in epicondylitis [4-9]. PRP therapies
are multitargeted approaches able to release a large pool
of signals, producing an instructional biological micro-
environment for local and migrating cell activities.
Moreover, PRPs modulate inflammation and angiogen-
esis largely because of their ability to secrete high levels
of growth factors and chemokines [10].
Different PRP formulations can be obtained depending
on the preparation protocol, that is, single or double spin-
ning. Most double spinning and also the buffy coat-basedLtd. This is an Open Access article distributed under the terms of the Creative
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centration of platelets and leukocytes relative to peripheral
blood. These products are named L-PRP in contrast to
pure PRP that contains a moderate concentration of plate-
lets and absence or non-relevant concentration of leuko-
cytes, and are generally obtained after a soft single
spinning procedure [11]. The majority of clinical studies
published up to now (>90%) have examined the efficacy of
L-PRP injections with controversial results [12]. Assuming
that leukocyte-released proteases may compromise the
stability of platelet-released growth factors, better efficacy
might be achieved with pure PRP injections. Currently,
most published controlled studies have used corticoste-
roids as comparators. Instead, we propose lidocaine injec-
tions to avoid corticosteroids interference with the healing
mechanisms.
We will compare the clinical outcomes and sono-
graphic features of US-guided tenotomy combined with
pure PRP with the outcome of US-guided tenotomy
combined with lidocaine. This study protocol aims to
evaluate the potential of pure PRP associated with need-
ling for the treatment of epicondylitis.
Methods/Design
Study design
B-PRPtendon is a patient and assessor blinded superiority-
type randomized controlled trial; the study will be
conducted at Hospital Universitario Cruces (HUC). The
research protocol is approved by the Ethics Committee of
HUC and authorized by the Spanish Agency of Medicines.
A total of 80 patients will be randomly allocated into
one of two groups. The two groups are: US-guided per-
cutaneous needling tenotomy combined with PRP injec-
tion each alternate week for a total of two interventions;
and US-guided needling tenotomy combined with lido-
caine injection each alternate week for a total of two
interventions.
The study will run for 2 years. Recruitment will be for
12 months with final follow-up at 1 year post treatment
(Table 1).
Study population
Patients will be identified, and recruited in HUC and
from primary care settings of Bizkaia. Primary care phy-
sicians and research nurses will introduce the trial to the
patient and refer them to an orthopedic investigator for
screening and potential recruitment.
Patients will be treated and followed up in HUC at
6 weeks, 3, 6, and 12 months post treatment, and will be
required to attend an appointment for sonographic as-
sessments at 3, 6, and 12 months.
The inclusion criteria are: tendinopathy present in either
lateral or medial elbow; patients will have failed conserva-
tive treatment; baseline elbow pain >3/10 during resistedwrist extension; history of at least two periods of elbow
pain lasting >10 days; symptoms lasting at least 3 months
or longer; body mass index (BMI) between 20 and 35;
commitment to comply with all study procedures; and the
patient must give written informed consent.
Patients may not enter the study if any of the following
apply: presence of full tendon tear; BMI >35; systemic
autoimmune rheumatologic disease (connective tissue
diseases and systemic necrotizing vasculitis); poorly con-
trolled diabetes mellitus (glycosylated hemoglobin above
9%); blood disorders (thrombopathy, thrombocytopenia,
anemia with Hb <9); patient receiving immunosuppres-
sive treatments; received local steroid injection within
3 months of randomization; received non-steroidal anti-
inflammatory, opioids, or oral corticosteroids within
15 days before inclusion in the study; severe heart disease;
patients unable to comply with scheduled visits, for work,
or spend long periods away from their habitual residence;
patients with active cancer or cancer diagnosed in the last
5 years; analytical diagnosis of hepatitis B, C, or HIV infec-
tion; pregnant or lactating; or people who are taking a
drug in clinical investigation. Initial patient selection is
conditioned to the negative results in the analytical tests
for hepatitis B, C, or HIV infection.
PRP preparation
Peripheral venous blood is collected into three 9 mL
tubes containing 3.8% (wt/vol) sodium citrate. The antic-
oagulated blood is centrifuged at 1,200 rpm for 6 min
and PRP is collected taking care to avoid contamination
with the buffy coat containing the leukocytes. Plasma is
kept at room temperature until intervention; the delay
between blood extraction and plasma administration will
not be >4 h. To avoid blood lipids in the PRP, patients
will fast or follow a fat-free diet during the 6 h prior to
blood extraction.
Just preceding PRP administration, 10% calcium chlor-
ide will be added, at a final concentration of 22.6 mM
(50 μL per 1 mL of PRP), and the 5 mL Luer Lok syringe
is filled with the activated PRP.
Procedures
Interventions are performed by two radiologists with ex-
tensive clinical experience in musculoskeletal interven-
tion procedures. Prior to needling and administration of
PRP or lidocaine, an exploratory echography is per-
formed to identify clefts of hypoechogenicity and/or
changes in vascularity, and baseline sonographic charac-
teristics are recorded, as described in Table 2 [13].
Needle tenotomy with PRP (or lidocaine)
Ultrasound-guided percutaneous needle tenotomy with
PRP (or lidocaine) will be performed each alternate week
for a total of two interventions. Blood will be drawn
Table 1 Outcome assessments
Study period
Enrollment Allocation Treatment Follow-up







DASH X X X X X
VAS X X X X X
Complications X X X X X
Ultrasound X X X X
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as described above. Using a single skin portal, local
anesthetic (2 mL of 1% lidocaine HCl 10 mg/mL) will be
injected into the subcutaneous tissue of the lateral or
medial elbow using a 20 G needle. Once the needle is in
place, the 5 mL Luer Lok syringe loaded with the treat-
ment is attached. Multiple longitudinal and transversal
penetrations of the tendon are performed, and 3 to
5 mL of PRP (or lidocaine) is delivered in multiple de-
pots during needling fenestrations. The injected volume
is adapted to the morphometric characteristics of each
patient. The same protocol with lidocaine is performed
in the control group.
Study assessments
Study assessments will include the Spanish version [14]
of the patient-reported outcome measure Disabilities ofTable 2 Sonographic assessments
Echotexture grading scale
0 Normal
1a Hypoechogenicity in less than one-third of the tendon
1b Hypoechogenicity in between one-third and two-thirds of
the tendon





1 Neovessels on the tendon surface
2 1 or 2 intratendinous neovessels
3 3 or more intratendinous neovessels
Tendon size (mm)
Calcificationsthe Arm, Shoulder and Hand (DASH-E, Spanish version
of the DASH, © Institute for Work & Health 2006), pain
outcome as measured by the visual analogue scale (VAS)
and changes in tendon structures and vascularity as
assessed by Doppler sonography (Table 2).
DASH is a patient-filled questionnaire based on the
patient’s subjective assessment of symptoms and abilities
to perform activities of daily living on the last week. The
range of available scores is 0 (best) to 100 (worst). The
questionnaire will be administered to patients at the base-
line and during their follow-up visits at 6 weeks, 3, 6, and
12 months.
The DASH disability/symptom score is calculated as
follows: DASH score = ((sum of n responses/n)–1) × 25,
where n is equal to the number of completed responses.Primary outcome measures
Successful treatment is defined as a reduction of >25%
in the DASH-E score at 6 months post-treatment. The
primary outcome measure is the percentage of patients
that achieve a successful treatment. We will examine if
the therapeutic success rates of the PRP and control
groups are statistically different.Secondary outcome measures
Secondary outcomes include: percentage of patients
that achieve a successful treatment at 6 weeks, 3, and
12 months; pain reduction as measured by changes in pain
rating on a visual analogue scale (VAS) with respect to
baseline; changes in echogenicity and vascularity as
assessed by Doppler sonography at 3, 6, and 12 months.
Frequency, severity, intensity, and duration of adverse
events will be recorded and the ratio of adverse events
in both groups compared.
A summary of the study design is shown in Figure 1.
Recruitment center
Hospital Universitario Cruces (HUC)
Primary Care
Patient pre-selection
Orthopedic Service HUC, informed 
consent, Blood tests, confirmation  







Needling + PRP 
Day 0 and Day 14
CONTROL: 2 interventions
Needling + lidocaine
Day 0 and Day 14
6 weeks, DASH, VAS, safety  
3 months, DASH, VAS. safety and 
sonographic assessment
6 months, DASH, VAS, safety and  
sonographic assessment
12 months, DASH, VAS, safety and 
sonographic assessment
Figure 1 Study flow chart.
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The minimum sample size required to achieve scientific-
ally valid results is 80. This sample size provides an 80%
potency to detect any significant difference between the
success rates in both groups (P1 = 0.93 and P2 = 0.65)
with a level of significance of 5%, being each arm formed
by 40 patient. We have assumed that the relative im-
provement with the PRP intervention is 1.43, assuming
that the differences between PRP and lidocaine would be
similar to the differences reported with corticoids [8],
and a patient loss of approximately 20%. However, this is
a randomized study which will help to gain insights into
feasibility of recruitment, and into the number of pa-
tients who become lost to follow-up.Randomization
Randomization will be performed in blocks of four, and
equal allocation ratio will be achieved by means of a free
informatics tool, EPIDAT3.1. Treatment assignments
will be conducted by an independent researcher atPrimary Care Investigation Unit of Bizkaia (UIAPB) who
will not interfere with the study.Blinding
All patients will be blinded to the treatment to which
they are allocated, thus peripheral blood is drawn even if
they are assigned to the control group. All outcome as-
sessors (orthopedists and radiologists) will be blinded,
but the radiologists applying the treatment will not.Adverse events
The patients will be instructed to record any discomfort
and/or any adverse reaction or event, whether or not it
is related to the intervention. The investigator will evalu-
ate and record the seriousness, intensity, expectedness,
and causality relationship, and a written communication
will be sent to the sponsor. Pertinent adverse events will
be notified to the licensing authorities (Ethics Commit-
tee of HUC and Spanish Agency of Medicines) by fax or
email.
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Categorical variables will be presented as rates and per-
centages. Demographic and clinical baseline characteris-
tics will be assessed to confirm comparability between
groups. If any clinically relevant data are unbalanced, we
will perform an adjusted analysis. Categorical variables
will be presented as frequencies and percentages, and we
will use the mean and standard deviation for data with a
normal distribution and median and interquartile range
for non-parametric data. Potential efficacy analysis will
be performed as intention to treat, comparing the per-
centage of patients that have achieved therapeutic
success in each group using the chi-squared test with
P < 0.05 deemed statistically significant. All statistical
analysis will be performed using the SAS 9.2 version.
Discussion
The present study had three principal objectives: first, to
investigate if pure PRP interventions reduce symptoms
and improve function by using the patient self-reported
DASH-E questionnaire; second, to examine the clinical
efficacy of needling combined with PRP injections in
pain; and third, to identify the potential structural
changes in the tendon after PRP treatment.
Multiple commercial protocols to prepare PRP are
currently available on the market. Depending on the
specific preparation protocol the qualitative and quan-
titative composition of PRP varies, and most likely so
do the biological effects. Current experimental research
postulates different efficiency among PRP formulations
[15,16], mainly leukocyte-rich PRP (L-PRP) and leukocyte-
depleted PRP (pure PRP). In fact, experimental research
has shown that L-PRP is more pro-inflammatory when
injected in rabbits [15], and it increases the levels of
metalloproteases when assayed in tenocyte cultures
compared to pure PRP [17].
On the basis of these preliminary experimental results,
and the clinical results in the conservative management
of knee OA in which L-PRP injections induced more
transient post-injection swelling and pain than pure PRP
[18], we expect fewer adverse reactions using pure PRP
(leukocyte-depleted).
To date, all controlled clinical trials in epicondylitis
have been performed with L-PRP [4-9]. In this pilot
study, we aim to examine the efficacy of pure PRP, and
potential comparative efficacy studies (L-PRP vs. pure
PRP) would be performed in a subsequent step forward.
Moreover, when compared to published clinical protocols
performed with L-PRP, we might anticipate improved
function and reduced pain using pure PRP associated
with the needling intervention.
Additionally, there is no consensus about the fre-
quency and number of PRP treatments in chronic injur-
ies. Thus, whether two interventions would be moreefficient than a single PRP application remains to be
clarified. Previous studies in tendinopathy have not
found any structural change after one PRP injection
pointing out that one single intervention may be insuffi-
cient to induce structural changes [19,20]. In this pilot
study we will explore whether two injections could mod-
ify the structural characteristics of the injured tendon. In
addition, the optimal volume of PRP has not been de-
fined so far thus we will adjust the injected volume (3–
5 mL) to the individual anatomical characteristics.
The results of this study will provide insights into the
effect of pure PRP in tendons and may contribute to
identifying the best protocol for PRP application in
tendinopathies.
Trial status
Recruitment commencement is planned by January 2014
and the expected average enrollment rate is four patients
every month. Data collection will continue for one year
after the last recruited patient.
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